Drug
Olmesartan Medoxomil
Olmesartan Medoxomil: highest development phase Post-Market, developed by Daiichi Sankyo. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| olmesartan medoxomil NCT00403481 | Post-Market | Hypertension |
| olmesartan medoxomil NCT00857285 | Phase 3 | Essential Hypertension |
| olmesartan medoxomil NCT00676845 | Phase 3 | Metabolic Syndrome |
Latest
No recent events.
Follow Olmesartan Medoxomil on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.